Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to be Presented at ASCO

Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to be Presented at ASCO PR Newswire WOBURN, Massachusetts and TOKYO, June 2, 2012 WOBURN, Massachusetts and TOKYO, June 2, 2012 /PRNewswire/ -- Significant improvements in time to progression (TTP) and overall survival (OS) observed in patients whose tumors were MET-high Hepatocellular carcinoma (HCC) is the most common primary liver cancer and on the [1]rise worldwide Phase 3 study among previously treated HCC patients with MET-high tumors is currently being planned with tivantinib ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE: 4568) today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC). The data are to be presented today at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) (abstract number 4006). The 107 patients in the trial had unresectable HCC and had disease progression after first-line therapy or were unable to tolerate the first-line therapy. Patients were randomized to receive tivantinib at 360 milligrams (mg) twice daily or 240 mg twice daily or placebo (2:1 tivantinib:placebo). The primary endpoint was time to progression (TTP) in the intent to treat (ITT) population.